amiloride has been researched along with Cancer of Prostate in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bedussi, F; Berruti, A; Dalla Volta, A; Ferrari, V; Fragni, M; Galli, D; Lazzari, B; Memo, M; Roca, E; Rossini, E; Sigala, S; Valcamonico, F; Vezzoli, S | 1 |
| Mitra, AK; Patel, M; Shah, S; Vadlapatla, RK | 1 |
| Jones, DA; Kassis, J; Kharait, S; Kloeker, S; Mamoune, A; Manos, E; Wells, A | 1 |
| Kim, KM; Lee, YJ | 1 |
| Cho, YL; Ha, KS; Han, JA; Kim, YM; Kwon, YG; Lee, H; Lee, KS; Lee, SJ; Namkoong, S | 1 |
| Bova, GS; Helenius, MA; Savinainen, KJ; Visakorpi, T | 1 |
| Sinha, AA; Wilson, MJ | 1 |
| Jankun, J; Keck, RW; Skrzypczak-Jankun, E; Swiercz, R | 1 |
| Bell, N; Bhatti, R; Gadarowski, J; Nasruddin, S; Ray, P | 1 |
9 other study(ies) available for amiloride and Cancer of Prostate
| Article | Year |
|---|---|
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.
Topics: Amiloride; Androgens; Androstenes; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Humans; Hydrochlorothiazide; Male; Mineralocorticoid Excess Syndrome, Apparent; Mineralocorticoids; Prostatic Neoplasms | 2017 |
Molecular expression and functional activity of sodium dependent multivitamin transporter in human prostate cancer cells.
Topics: Amiloride; Biotin; Cell Line, Tumor; Enzyme Inhibitors; Epithelial Sodium Channel Blockers; Humans; Hydrogen-Ion Concentration; Male; Ouabain; Prostatic Neoplasms; RNA, Messenger; Sodium-Potassium-Exchanging ATPase; Symporters; Vitamins | 2012 |
DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Topics: Amiloride; Animals; Antisense Elements (Genetics); Autocrine Communication; Carcinoma; Cell Movement; DNA, Complementary; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phospholipase C gamma; Prostatic Neoplasms; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Type C Phospholipases; Up-Regulation; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2004 |
Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway.
Topics: Adenocarcinoma; Amiloride; Apoptosis; Apoptosis Regulatory Proteins; Cell Line; Cell Line, Tumor; DNA, Complementary; Epithelial Cells; Humans; Male; Membrane Glycoproteins; Phosphoinositide-3 Kinase Inhibitors; Phosphoprotein Phosphatases; Prostate; Prostatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation.
Topics: Amiloride; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; HeLa Cells; Humans; Hydrogen-Ion Concentration; Intracellular Fluid; Male; Membrane Glycoproteins; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Topics: Amiloride; Blood Proteins; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Urokinase-Type Plasminogen Activator | 2006 |
Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
Topics: Amiloride; Animals; Humans; Male; Metalloendopeptidases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Plasminogen Activators; Prostatic Neoplasms; Transplantation, Heterologous; Urokinase-Type Plasminogen Activator | 1993 |
Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Topics: Amiloride; Animals; Antineoplastic Agents; Base Sequence; Benzamidines; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, SCID; Molecular Sequence Data; Penicillins; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Prostatic Neoplasms; Transplantation, Heterologous; Urokinase-Type Plasminogen Activator | 1997 |
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Topics: Adenocarcinoma; Amiloride; Animals; Diuretics; Lung Neoplasms; Male; Neoplasms, Experimental; Plasminogen Activators; Prostatic Neoplasms; Rats; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1998 |